The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Abstract
BACKGROUND: The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS: In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS: A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], -1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS: In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000503 · Cited by 2,497
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Atrial fibrillation complicating the course of degenerative mitral regurgitation
Grigioni, F., Avierinos, J.-F., Ling, L. H., Scott, C. G., Bailey, K. R., Tajik, A. J., Frye, R. L., & Enriquez-Sarano, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01922-8 · Cited by 386
Turpie, A. G. G., Hirsh, J., Gunstensen, J., Nelson, H., & Gent, M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92070-3 · Cited by 315
On the Restricted Mean Survival Time Curve in Survival Analysis
Zhao, L., Claggett, B., Tian, L., Uno, H., Pfeffer, M. A., Solomon, S. D., Trippa, L., & Wei, L. J. (2016) · Biometrics · doi:10.1111/biom.12384 · Cited by 264
Avezum, A., Lopes, R. D., Schulte, P. J., Lanas, F., Gersh, B. J., Hanna, M., Pais, P., Erol, C., Diaz, R., Bahit, M. C., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.014807 · Cited by 243
Self-citationSun, J. C., Davidson, M. J., Lamy, A., & Eikelboom, J. W. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60780-7 · Cited by 241
Uno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., & Wei, L.-J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1741 · Cited by 220
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
Kim, D. H., Uno, H., & Wei, L.-J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2922 · Cited by 207
Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P. (2017) · Circulation · doi:10.1161/circulationaha.116.026714 · Cited by 166
What is ‘valvular’ atrial fibrillation? A reappraisal
De Caterina, R., & Camm, A. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu352 · Cited by 164
Durães, A. R., Roriz, P. D. S., Nunes, B. D. A., Albuquerque, F. P. E., de Bulhões, F. V., Fernandes, A. M. S., & Aras, R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0124-1 · Cited by 116
Guimarães, P. O., Pokorney, S. D., Lópes, R. D., WOJDYLA, D. M., Gersh, B. J., Giczewska, A., Carnicelli, A., Lewis, B. S., Hanna, M., Wallentin, L. C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23178 · Cited by 115
Self-citationJawitz, O. K., Wang, T. Y., Lópes, R. D., Chavez, A., Boyer, B., Kim, H., Anstrom, K. J., Becker, R. C., Blackstone, E. H., Ruel, M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.06.014 · Cited by 81
Self-citationKarthikeyan, G., Connolly, S. J., Ntsekhe, M., Benz, A. P., Rangarajan, S., Lewis, G., Yun, Y., Sharma, S. K., Maklady, F., Elghamrawy, A., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.018 · Cited by 63
Siontis, K. C., Yao, X., Gersh, B. J., & Noseworthy, P. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026793 · Cited by 59
Pasciolla, S., Zizza, L., Le, T. P., & Wright, K. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00939-x · Cited by 38
A Brief Overview of Restricted Mean Survival Time Estimators and Associated Variances
Nemes, S., Bülow, E., & Gustavsson, A. (2020) · Stats · doi:10.3390/stats3020010 · Cited by 14
Cited by
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., Ajmone Marsan, N., Barili, F., Bonaros, N., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,072
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Beyersdorf, F., Vahanian, A., Milojevic, M., Praz, F., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab389 · Cited by 622
Metadata
- Authors
- Guimarães, H. P., Lopes, R. D., de Barros e Silva, P. G. M., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Hoffmann-Filho, C. R., de Lemos Soares Patriota, R., Leiria, T. L. L., Lamprea, D., Precoma, D. B., Atik, F. A., Silveira, F. S., Farias, F. R., Barreto, D. O., Almeida, A. P., Zilli, A. C., de Souza Neto, J. D., Cavalcante, M. A., Figueira, F. A. M. S., Kojima, F. C. S., Damiani, L., Santos, R. H. N., Valeis, N., Campos, V. B., Saraiva, J. F. K., Fonseca, F. H., Pinto, I. M., Magalhães, C. C., Ferreira, J. F. M., Alexander, J. H., Pavanello, R., Cavalcanti, A. B., & Berwanger, O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-26
- Volume
- 383
- Issue
- 22
- Pages
- 2117-2126
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098781229
- Cited by
- 289
- References
- 25
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.